1. | geal4313 | |
2. | byardstreet | |
3. | acam6505 | |
4. | pilfer19 | |
5. | amarilys3905 |
1. | geal4313 | |
2. | byardstreet | |
3. | acam6505 | |
4. | pilfer19 | |
5. | amarilys3905 |
1. | byardstreet 02/28/2018 BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema |
2. | acam6505 02/18/2018 Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. |
3. | pilfer19 06/25/2018 BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan |
4. | geal4313 01/26/2018 Global Pharmaceutical Over-the-counter Latest Advancements Boosting OTC Drugs Market Growth |
5. | byardstreet 01/23/2018 Double for the price target here of $10 |
6. | geal4313 01/23/2018 More merger info: BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases |
7. | byardstreet 06/05/2018 BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera |
8. | byardstreet 07/26/2018 BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine |
9. | geal4313 01/22/2018 BioCryst Pharmaceuticals Merging |
10. | geal4313 02/27/2018 BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results |